transformants, the 40 -70 kb plasmid was detected, occasionally together with a 250 kb plasmid, which might result from the fusion of plasmids of smaller sizes. Southern hybridization using bla CTX-M , IncF and IncR sequences as probes demonstrated that the 40 -70 kb plasmid was of the IncR type and carried the bla CTX-M-15 gene.
Amongst the 24 K. pneumoniae isolates, 17/24 were from pets that underwent cytostomy or perineal urethrostomy in the same referral hospital, two surgical procedures that aim at solving bladder or urethral occlusions due to abundant crystals in urine in healthy animals. Of the seven others, three (strains 24492, 24418 and 24419; Table 1 ) were from animals visiting two neighbouring regular veterinary clinics. Interestingly, two of them (24492 and 24418) were from animals hospitalized for similar urinary tract surgery in the above-mentioned referral hospital a few weeks before, and one of these two dogs died after a severe chronic infectious cystitis, a classical post-operative complication of urethrostomy. The third isolate (24419) was recovered 2 months later in the same regular clinic as isolate 24418, but from a diabetic dog that had no history with the referral hospital. No epidemiological data could be obtained for the four remaining K. pneumoniae isolates, which were recovered from different veterinary clinics located in the same geographical area.
This study reports recurrent veterinary hospital-acquired infections in pets with a ciprofloxacin-resistant CTX-M-15-producing K. pneumoniae ST15 clone and this mirrors the situation observed for nosocomial infections in human hospitals. A spread of this clone outside the veterinary hospital through post-operative follow-up is also suggested. Of concern, this clone has been reported in humans and the hypothesis of a direct human origin, such as from a pets' owner, remains open. However, since the ST131/CTX-M-15 E. coli clone has also been reported in pets, 5 a transfer to K. pneumoniae of the bla CTX-M-15 gene from IncFII-type plasmids found in E. coli is also plausible. Finally, this study is also the first report of a bla CTX-M-15 gene on an IncR-type plasmid in animals, a combination only recently reported in humans. 3 
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Pseudomonas aeruginosa, possibly because of poor permeation across the outer membrane barrier and/or reduced binding to penicillin-binding proteins. 1 However, the role of multidrug efflux systems has not been examined so far. Three multidrug efflux systems have been reported to export b-lactams in P. aeruginosa, namely (from least to most effective) MexXY-OprM, MexCD-OprJ and MexAB-OprM. 2 We wondered whether temocillin could be the substrate of one or several of these transporters.
Temocillin (Eumedica, Brussels, Belgium) and ticarcillin (disodium salt; Sigma -Aldrich, St Louis, MO, USA) were tested against: (i) the wild-type reference strain PAO1; (ii) a panel of laboratory strains with specific disruption(s) of the gene(s) encoding the three transporters mentioned above and MexEF-OprN, another efflux pump accommodating fluoroquinolones, trimethoprim and chloramphenicol, but not b-lactams, 2 and producing different levels of AmpC; (iii) clinical isolates from patients hospitalized in intensive care units (ICUs) with hospital-acquired pneumonia (HAP); and (iv) strains from cystic fibrosis patients that were found to be hypersusceptible to carbenicillin and ticarcillin (Tic HS phenotype) due to mutations in mexA or mexB. 3 MICs were determined by microdilution in Mueller -Hinton broth (pH 7.4, 24 h) without or with the broad-spectrum efflux inhibitor Phe-Arg-b-naphthylamide (PAbN; 50 mg/L; Sigma -Aldrich). 4 The expression of mexA and mexX was measured by quantitative realtime PCR, and that of mexC and mexE was measured by semiquantitative RT-PCR. mexA, mexB and oprM were sequenced in strains from cystic fibrosis patients. 3 The MIC of temocillin for PAO1 was ≥256 mg/L, but fell to 64 mg/L when tested in the presence of PAbN, a broad-spectrum competitive inhibitor of efflux transporters (Table 1) , suggesting a role of active efflux in the intrinsic high-level resistance of P. aeruginosa to temocillin. The magnitude of the inhibitory effect of PAbN, however, varies depending on the substrate. 4 To better quantify the impact of efflux on temocillin MICs, and also to identify the transporter(s) responsible for its efflux, we used isogenic strains deficient in the main efflux systems. Disruption of MexCD-OprJ, MexEF-OprN or MexXY only slightly affected the temocillin MIC (2-3 log 2 reduction), consistent with the strongly repressed expression of these three systems in wild-type strains. In contrast, disruption of mexB, mexAB, oprM or mexAB-oprM decreased MICs to values as low as 2-4 mg/L, with a minimal additional effect of PAbN. Conversely, overexpression of mexAB, but not of mexXY, further increased the temocillin MIC compared with PAO1. This clearly indicates that MexAB-OprM-driven efflux strongly contributes to the intrinsic resistance of P. aeruginosa to temocillin, while the other Mex systems only play a minor role. We also confirmed the stability of temocillin to AmpC.
To examine the clinical relevance of our observations, we measured temocillin MICs for isolates collected from ICU patients with HAP. All values were high, but those from isolates overexpressing mexA were higher than those for PAO1, corroborating the importance of this efflux system in temocillin resistance. In parallel, we found that isolates obtained from cystic fibrosis patients and showing hypersusceptibility to ticarcillin were also hypersusceptible to temocillin, with MICs ranging between 1 and 4 mg/L in most cases. Interestingly enough, however, the MICs for some isolates with single nucleotide mutations in MexA (G72S and Y197C) remained moderately elevated (32 mg/L), suggesting that these mutated proteins remained partly functional.
Noteworthy, when considering all isolates examined here, differences between temocillin and ticarcillin MICs were much greater in isolates producing a functional or partially functional MexAB-OprM pump than in deficient strains (with temocillin MICs being 3 -5 log 2 dilutions higher than those of ticarcillin). This suggests that temocillin is a preferential substrate for the MexAB-OprM transporter compared with ticarcillin, pointing to a potential role of the 6-a-methoxy substituent in its recognition and efflux.
While intrinsic resistance of P. aeruginosa to temocillin makes this antibiotic unusable in most conventional clinical set-ups, we see here that impairment of efflux lowers the MICs to values below the current clinical susceptibility breakpoint for Enterobacteriaceae (16 mg/L; UK and Belgium) or even the pharmacokinetic/pharmacodynamic breakpoint proposed for a 4 g daily dose (8 mg/L). 5 This may further trigger current efforts in designing clinically useful inhibitors of the MexAB-OprM transporter, since such combined therapy could provide the clinician with a useful alternative to current antipseudomonal b-lactams, especially if considering temocillin's remarkable b-lactamase stability. The present data may also have potential immediate application for cystic fibrosis patients. These patients can be infected by Burkholderia cepacia, against which temocillin is active and, therefore, commonly used. 1 Because of the large prevalence of P. aeruginosa isolates with the hypersusceptible Tic HS phenotype in this patient population, 3 temocillin could contribute to their eradication as well. Testing for temocillin susceptibility of P. aeruginosa isolated from cystic fibrosis patients appears, therefore, potentially useful.
Sir, The emergence of multidrug-resistant Salmonella infection is an ever-increasing problem and is a cause for serious global concern. Resistance to third-generation cephalosporins in Salmonella has been attributed to the production of extendedspectrum b-lactamases (ESBLs), but resistance mediated by AmpC and KPC or metallo-b-lactamases ('MBLs') has also been reported. 1 In particular, the AmpC b-lactamases reported in non-typhoidal Salmonella (NTS) are derivatives of CMY, DHA-1 and ACC-1, 1 although ACC-1-producing Salmonella Typhi has been recently identified in India.
2
A Salmonella enterica serovar Typhi (designated B729) isolate was isolated from the blood culture of a child admitted to a hospital in Salem, Tamil Nadu, in December 2009. Species identification and antibiotic susceptibility were performed using an automated system (VITEK-2, bioMérieux Inc.). The isolate was further confirmed by serotyping using specific antiserum. This isolate was resistant to all the b-lactams (except carbapenems), but susceptible to non-b-lactam antibiotics. MICs of various antibiotics were determined using the agar dilution method, and susceptibility data were interpreted using EUCAST breakpoints (version 1.3; January 2011), while tetracycline and nalidixic acid susceptibilities were interpreted as recommended by CLSI guidelines (January 2011), as EUCAST breakpoints are not defined. B729 showed elevated MICs of all the b-lactams except carbapenems (,0.25 mg/L), co-trimoxazole (,1 mg/L), chloramphenicol (4 mg/L), aminoglycosides (,0.5 mg/L), tetracycline (2 mg/L), nalidixic acid (2 mg/L) and ciprofloxacin (,0.015 mg/L).
The presence of AmpC was determined by phenotypic methods, namely an AmpC disc test and a modified three-dimensional test.
PCR assays for the genes encoding b-lactamases 3 showed that B729 carried bla CMY-2. In addition, PCR mapping experiments 4 and sequencing analysis revealed that the bla CMY-2 was flanked by ISEcp1 and a blc gene, similar to the NTS isolates previously reported in the USA, Taiwan and Europe.
Plasmid analysis using the Kieser technique revealed that B729 harboured three plasmids, with respective sizes of 90, 70 and 25 kb, using Escherichia coli NCTC 50192 as a reference marker. To determine whether the AmpC phenotype was transferable, transconjugation experiments were attempted using a ciprofloxacin-resistant clinical isolate of Salmonella Typhimurium and the azide-resistant E. coli J53 as the recipient. Transconjugants were selected on MacConkey agar plates containing cefotaxime (2 mg/L) and ciprofloxacin (1 mg/L) or sodium azide (200 mg/L). The AmpC phenotype was successfully transferred to both of the species tested. The plasmids of the transconjugants showing an AmpC phenotype were typed by PCR-based replicon typing. 5 The plasmid profile revealed that the E. coli J53-p729A transconjugant carried a bla CMY-2 -positive 70 kb plasmid that belonged to the IncA/C incompatibility type (Table 1) . 
